Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
about
An update on the management of breast cancer in Africa.A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degenerationA phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.Dynamics of tumor hypoxia in response to patupilone and ionizing radiationBreast cancer biomarkers and molecular medicine.Trastuzumab-based combination therapy for breast cancer.Targeted therapy in breast cancer: the HER-2/neu gene and protein.The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell linesA randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.Weekly paclitaxel in the adjuvant treatment of breast cancer.Combined treatment strategies for microtubule stabilizing agent-resistant tumors.Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience.HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.A phase II study of docetaxel in patients with metastatic carcinoid tumors.Suppressive Effects of Bee Venom Acupuncture on Paclitaxel-Induced Neuropathic Pain in Rats: Mediation by Spinal α₂-Adrenergic Receptor.Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer.Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor.
P2860
Q30235608-9FE80089-9F1B-47E2-AD1E-C29B391B3AD7Q33112264-9D41D1AE-4C66-451F-9069-30FBD071C05CQ33387547-F684F838-E3AC-4753-8B60-310ABE607D5EQ33838622-1E1BC047-A626-418E-9727-7CC2095CF2A0Q34516719-3FE990C8-9CB0-4D4D-9D99-725CA7FB9C5DQ35543887-3D3C3CEA-424A-4600-B848-0CCF0FFC4361Q35609686-F92BDA2C-C911-4DE1-9FA3-1ABAC0FAF6E6Q35648508-47F96DF1-DAC1-490D-ABC5-F553C4A2E840Q36753310-04CF55C0-45AF-48B1-A229-AEB1240A7CF0Q36892821-AEF715C9-4F05-4F6C-B18D-75A6F88DAE71Q37133208-78D79C1C-F245-4851-9EB5-7581C9939A54Q37346811-CFCCB9CD-0F6F-45BD-A7BA-8DCB0B527A1BQ38908225-34906E0E-69ED-4743-BD92-3AD807810B38Q43619689-C36B4158-1197-4382-B993-818DAB3866C6Q44992743-4E331BE7-5138-470B-AC61-BA0F0E0E3BF1Q45114038-035A98F8-5DA0-4349-9EE2-A1107FFB2549Q47098761-8BD54FF0-DAA8-40F0-B731-FD80B877AD06Q47119995-9AD498A0-80D4-4B5F-B70F-61870EFF1454Q52649466-0A12C164-9CAE-45AE-8C71-25F75C97D4EA
P2860
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Taxanes for breast cancer: an ...... phase II and phase III trials.
@ast
Taxanes for breast cancer: an ...... phase II and phase III trials.
@en
Taxanes for breast cancer: an ...... phase II and phase III trials.
@nl
type
label
Taxanes for breast cancer: an ...... phase II and phase III trials.
@ast
Taxanes for breast cancer: an ...... phase II and phase III trials.
@en
Taxanes for breast cancer: an ...... phase II and phase III trials.
@nl
prefLabel
Taxanes for breast cancer: an ...... phase II and phase III trials.
@ast
Taxanes for breast cancer: an ...... phase II and phase III trials.
@en
Taxanes for breast cancer: an ...... phase II and phase III trials.
@nl
P356
P1476
Taxanes for breast cancer: an ...... phase II and phase III trials.
@en
P2093
J A Sparano
P304
32-40; discussion 41-2
P356
10.3816/CBC.2000.N.002
P407
P577
2000-04-01T00:00:00Z